Pulmatrix PULM

NASDAQ PULM

$1.48 +0.11 (+8.03%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap5.37 Mn

P/E-1.32

Div. Yield0.00

Add ratio to table…

About

Pulmatrix, Inc. is a biopharmaceutical company that develops novel inhaled therapeutic products using its proprietary iSPERSE™ dry powder delivery technology. The iSPERSE™ platform engineers small, dense particles with high dispersibility and efficient delivery to the airways, and it can be formulated with a broad range of drug substances, including small molecules and biologics. The company’s pipeline includes PUR3100, an inhaled formulation of dihydroergotamine for the acute treatment of migraine; PUR1800, an inhaled kinase inhibitor targeting p38MAPK, Src and Syk for acute exacerbations of chronic obstructive pulmonary disease; and PUR1900, an inhaled itraconazole formulation for allergic bronchopulmonary aspergillosis in patients with asthma or cystic fibrosis. All product candidates are designed to improve local drug delivery while limiting systemic exposure. Development of these candidates has been paused as the company explores opportunities to monetize its assets and the iSPERSE™ technology itself.

Pulmatrix has historically generated revenue through licensing and collaboration agreements rather than product sales. The development and commercialization agreement with Cipla for the PUR1900 program has provided milestone payments and royalties, accounting for the majority of the company’s revenue in prior periods. In the nine months ended September 30, 2025, no product sales were recorded and revenue was zero, compared with $7.8 million in the same period of 2024, which reflected the wind‑down activities of the PUR1900 Phase 2b trial. The company currently reports no product sales and is seeking to monetize its existing clinical assets, including PUR3100, PUR1800 and PUR1900, as well as to license the iSPERSE™ platform to third parties. Its cash and cash equivalents stood at $4.8 million as of September 30, 2025, and the accumulated deficit was $301.4 million.

Pulmatrix’s competitive position rests on the proprietary iSPERSE™ technology, which offers enhanced drug loading and delivery efficiency relative to traditional lactose‑blend dry powder inhalers, resulting in reduced total inhaled powder mass and improved dosing efficiency. As of September 30, 2025, the company held approximately 146 granted patents worldwide, including 18 U. S. patents with expiration dates ranging from 2026 to 2043, and an in‑licensed portfolio related to kinase inhibitors comprising about 283 granted patents, 33 of which are U. S. patents expiring between 2029 and 2035. This extensive intellectual property estate, combined with expertise in particle engineering and dry powder formulation, creates a barrier to entry and differentiates Pulmatrix from other inhaled therapy developers. The company also emphasizes a favorable safety and tolerability profile for its iSPERSE™‑based formulations, as demonstrated in early clinical studies of PUR3100 and PUR1800.

The company’s customer base consists primarily of collaboration partners. Pulmatrix co‑developed PUR1900 with Cipla, under which Cipla handles development and commercialization outside the United States while Pulmatrix retains a 2 % royalty on net sales from those territories. Following the MannKind Transaction, Pulmatrix entered into a Master Services Agreement with MannKind Corporation to obtain development services for iSPERSE™‑based formulations, including dry powder production and process support. These relationships represent the company’s principal sources of non‑dilutive funding and technical assistance as it pursues strategic alternatives, including the pending merger with Cullgen.

Investment Thesis

▲ Bull case

The merger with Eos SENOLYTIX places Pulmatrix at the forefront of the gerotherapeutics field which aims to treat aging as a modifiable condition rather than a collection of separate diseases. Eos MitoXcel platform targets mitochondrial membrane potential and senescent cell clearance two mechanisms that have shown robust effects in aged mice including fat loss lean gain and improved physical function. These preclinical results suggest a potential advantage over existing GLP1 therapies which often reduce both fat and lean muscle and are associated with rebound weight gain after discontinuation. If the platform translates to humans it could capture a meaningful share of the rapidly growing obesity and aging market which is projected to exceed hundreds of billions of dollars in the coming decades.
The concurrent private placement that accompanies the merger will deliver approximately $19,000,000 in gross proceeds to the combined entity. This capital infusion is earmarked for advancing the MitoXcel platform including the lead candidate PTC 2105 through preclinical toxicology and into early phase human studies. Having a funded runway reduces the immediate financing risk that often plagues early stage biotech ventures and allows management to focus on achieving key milestones rather than scrambling for additional dollars. The availability of funds also supports the pursuit of combination studies with GLP1 agents to evaluate potential synergistic effects on body composition and healthspan.
Pulmatrix's proprietary iSPERSE dry powder technology could be adapted to deliver geropeptides directly to the lung or systemic circulation offering a differentiated delivery approach that may improve pharmacokinetics and reduce systemic side effects. The iSPERSE platform has already demonstrated capability to formulate small molecules peptides proteins and nucleic acids for efficient deep lung deposition. Applying this technology to the MitoXcel peptides could produce a product with prolonged lung retention and controlled release which may enhance therapeutic index compared with conventional subcutaneous injection. Such a delivery innovation could become a valuable asset for partnership discussions with larger pharmaceutical companies seeking novel routes for aging therapeutics.
Following the close of the transaction pre merger Pulmatrix shareholders are expected to own roughly 6% of the combined company while former Eos holders will control about 94% of the equity. This structure means that any upside generated by successful clinical development of PTC 2105 or other pipeline candidates will accrue primarily to the new entity but the existing Pulmatrix stake provides a leveraged exposure to potential value creation. If the combined firm achieves milestones such as IND filing positive phase two data or partnership agreements the market may re rate the stock based on the projected net present value of the gerotherapeutic platform rather than the legacy inhaled assets. The leveraged upside could generate significant returns for Pulmatrix investors despite the modest postmerger ownership percentage.
The gerotherapeutics sector is attracting increasing attention from large pharma and venture investors as aging populations expand and the limitations of symptomatic therapies become more apparent. Companies that can demonstrate a mechanism that targets fundamental aging processes such as mitochondrial dysfunction or senescent cell accumulation are viewed as potential platforms for broad disease modification rather than single indication drugs. Eos MitoXcel platform fits this narrative and could therefore become a target for acquisition partnership or licensing deals even before late stage data are available. Such strategic interest could provide non dilutive funding options or accelerate timelines through shared development costs. The possibility of a big pharma partnership adds an additional layer of optionality to the investment thesis beyond pure clinical success.

The merger with Eos SENOLYTIX places Pulmatrix at the forefront of the gerotherapeutics field which aims to treat aging as a modifiable condition rather than a collection of separate diseases. Eos MitoXcel platform targets mitochondrial membrane potential and senescent cell clearance two mechanisms that have shown robust effects in aged mice including fat loss lean gain and improved physical function. These preclinical results suggest a potential advantage over existing GLP1 therapies which often reduce both fat and lean muscle and are associated with rebound weight gain after discontinuation. If the platform translates to humans it could capture a meaningful share of the rapidly growing obesity and aging market which is projected to exceed hundreds of billions of dollars in the coming decades.
The concurrent private placement that accompanies the merger will deliver approximately $19,000,000 in gross proceeds to the combined entity. This capital infusion is earmarked for advancing the MitoXcel platform including the lead candidate PTC 2105 through preclinical toxicology and into early phase human studies. Having a funded runway reduces the immediate financing risk that often plagues early stage biotech ventures and allows management to focus on achieving key milestones rather than scrambling for additional dollars. The availability of funds also supports the pursuit of combination studies with GLP1 agents to evaluate potential synergistic effects on body composition and healthspan.
Pulmatrix's proprietary iSPERSE dry powder technology could be adapted to deliver geropeptides directly to the lung or systemic circulation offering a differentiated delivery approach that may improve pharmacokinetics and reduce systemic side effects. The iSPERSE platform has already demonstrated capability to formulate small molecules peptides proteins and nucleic acids for efficient deep lung deposition. Applying this technology to the MitoXcel peptides could produce a product with prolonged lung retention and controlled release which may enhance therapeutic index compared with conventional subcutaneous injection. Such a delivery innovation could become a valuable asset for partnership discussions with larger pharmaceutical companies seeking novel routes for aging therapeutics.
Following the close of the transaction pre merger Pulmatrix shareholders are expected to own roughly 6% of the combined company while former Eos holders will control about 94% of the equity. This structure means that any upside generated by successful clinical development of PTC 2105 or other pipeline candidates will accrue primarily to the new entity but the existing Pulmatrix stake provides a leveraged exposure to potential value creation. If the combined firm achieves milestones such as IND filing positive phase two data or partnership agreements the market may re rate the stock based on the projected net present value of the gerotherapeutic platform rather than the legacy inhaled assets. The leveraged upside could generate significant returns for Pulmatrix investors despite the modest postmerger ownership percentage.
The gerotherapeutics sector is attracting increasing attention from large pharma and venture investors as aging populations expand and the limitations of symptomatic therapies become more apparent. Companies that can demonstrate a mechanism that targets fundamental aging processes such as mitochondrial dysfunction or senescent cell accumulation are viewed as potential platforms for broad disease modification rather than single indication drugs. Eos MitoXcel platform fits this narrative and could therefore become a target for acquisition partnership or licensing deals even before late stage data are available. Such strategic interest could provide non dilutive funding options or accelerate timelines through shared development costs. The possibility of a big pharma partnership adds an additional layer of optionality to the investment thesis beyond pure clinical success.

▼ Bear case

The proposed transaction results in substantial dilution for existing Pulmatrix shareholders who will retain only about 6% ownership of the combined company after the merger closes. This means that the majority of any future value creation will flow to the former Eos investors and any new capital partners involved in the private placements. Should the combined entity fail to meet clinical or commercial expectations the downside for Pulmatrix investors is magnified because their stake is small relative to the total enterprise value. The high dilution also reduces the voting influence of legacy Pulmatrix shareholders on key corporate decisions including potential future financings or strategic shifts. Investors must weigh the possibility of owning a minor slice of a risky biotech venture against the alternative of holding a larger position in a standalone company.
Eos MitoXcel platform remains at the preclinical stage with data derived primarily from mouse models and there is limited evidence of safety or efficacy in human subjects. Translating mitochondrial membrane potential modulation or senescent cell clearance from rodents to people carries inherent uncertainty and many promising aging targets have failed in clinical trials due to lack of efficacy or unexpected toxicities. The lead candidate PTC 2105 has not yet undergone IND enabling studies and any delay or negative outcome in those studies would postpone the anticipated clinical timeline and increase cash burn. Investors should recognize that the promising preclinical phenotype does not guarantee a therapeutic benefit in humans especially for a mechanism that intervenes in fundamental cellular processes.
While the $19,000,000 private placement provides an initial cash cushion the combined company will likely require substantially more funding to advance PTC 2105 through phase one phase two and potentially pivotal trials as well as to develop manufacturing capabilities for a peptide therapeutic. Typical peptide development programs can consume tens of millions of dollars per year especially when including toxicology glp compliance and scale up activities. If the company is unable to secure additional financing on favorable terms it may face further dilution through down round financings or be forced to curtail research programs. The reliance on future capital markets adds risk given the current volatility in biotech funding environments and the company's limited operating history as a combined entity.
Pulmatrix's legacy inhaled assets including migraine and COPD programs are currently being held for out licensing or sale and have generated negligible revenue in recent quarters. The company reported zero product revenue for the Q1 FY26 and minimal research and development spending as it suspends clinical activities while pursuing the merger. This lack of near term cash flow means the combined entity will depend almost entirely on the success of the gerotherapeutic pipeline to generate value. If the out licensing efforts fail to produce meaningful upfront payments or royalties the company will have limited financial flexibility to support operations beyond the cash raised in the private placement. Investors should consider that the investment thesis is now tightly coupled to the performance of a single early stage asset rather than a diversified portfolio.
Gerotherapeutic molecules that target mitochondrial function or senescent cells represent a novel therapeutic class and may encounter heightened scrutiny from regulatory agencies such as the FDA and EMA regarding safety long term effects and appropriate clinical trial endpoints. The absence of established biomarkers for aging modification could complicate demonstration of clinical benefit and increase the likelihood of trial failure or regulatory delay. Additionally Pulmatrix has recently experienced difficulties completing a merger with Cullgen due to delays at the China Securities Regulatory Commission indicating potential execution challenges in complex cross border transactions. The combination of scientific novelty regulatory uncertainty and execution risk creates a multifaceted risk profile that may weigh heavily on the stock price unless clear progress is demonstrated quickly.

The proposed transaction results in substantial dilution for existing Pulmatrix shareholders who will retain only about 6% ownership of the combined company after the merger closes. This means that the majority of any future value creation will flow to the former Eos investors and any new capital partners involved in the private placements. Should the combined entity fail to meet clinical or commercial expectations the downside for Pulmatrix investors is magnified because their stake is small relative to the total enterprise value. The high dilution also reduces the voting influence of legacy Pulmatrix shareholders on key corporate decisions including potential future financings or strategic shifts. Investors must weigh the possibility of owning a minor slice of a risky biotech venture against the alternative of holding a larger position in a standalone company.
Eos MitoXcel platform remains at the preclinical stage with data derived primarily from mouse models and there is limited evidence of safety or efficacy in human subjects. Translating mitochondrial membrane potential modulation or senescent cell clearance from rodents to people carries inherent uncertainty and many promising aging targets have failed in clinical trials due to lack of efficacy or unexpected toxicities. The lead candidate PTC 2105 has not yet undergone IND enabling studies and any delay or negative outcome in those studies would postpone the anticipated clinical timeline and increase cash burn. Investors should recognize that the promising preclinical phenotype does not guarantee a therapeutic benefit in humans especially for a mechanism that intervenes in fundamental cellular processes.
While the $19,000,000 private placement provides an initial cash cushion the combined company will likely require substantially more funding to advance PTC 2105 through phase one phase two and potentially pivotal trials as well as to develop manufacturing capabilities for a peptide therapeutic. Typical peptide development programs can consume tens of millions of dollars per year especially when including toxicology glp compliance and scale up activities. If the company is unable to secure additional financing on favorable terms it may face further dilution through down round financings or be forced to curtail research programs. The reliance on future capital markets adds risk given the current volatility in biotech funding environments and the company's limited operating history as a combined entity.
Pulmatrix's legacy inhaled assets including migraine and COPD programs are currently being held for out licensing or sale and have generated negligible revenue in recent quarters. The company reported zero product revenue for the Q1 FY26 and minimal research and development spending as it suspends clinical activities while pursuing the merger. This lack of near term cash flow means the combined entity will depend almost entirely on the success of the gerotherapeutic pipeline to generate value. If the out licensing efforts fail to produce meaningful upfront payments or royalties the company will have limited financial flexibility to support operations beyond the cash raised in the private placement. Investors should consider that the investment thesis is now tightly coupled to the performance of a single early stage asset rather than a diversified portfolio.
Gerotherapeutic molecules that target mitochondrial function or senescent cells represent a novel therapeutic class and may encounter heightened scrutiny from regulatory agencies such as the FDA and EMA regarding safety long term effects and appropriate clinical trial endpoints. The absence of established biomarkers for aging modification could complicate demonstration of clinical benefit and increase the likelihood of trial failure or regulatory delay. Additionally Pulmatrix has recently experienced difficulties completing a merger with Cullgen due to delays at the China Securities Regulatory Commission indicating potential execution challenges in complex cross border transactions. The combination of scientific novelty regulatory uncertainty and execution risk creates a multifaceted risk profile that may weigh heavily on the stock price unless clear progress is demonstrated quickly.

Product Or Service Breakdown of Revenue (2023)

Peer group

Peer Comparison

Companies in the Pharmaceuticals

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	primary	643.26 Bn	30.58	6.57	60.73 Bn
2	ABBV	AbbVie Inc.	primary	443.31 Bn	70.19	6.89	70.82 Bn
3	MRK	Merck & Co., Inc.	primary	364.74 Bn	115.10	5.48	53.91 Bn
4	NVS	Novartis Ag	primary	266.46 Bn	9.25	3.88	9.59 Bn
5	PFE	Pfizer Inc	primary	158.57 Bn	36.30	2.49	63.19 Bn
6	SNY	Sanofi	primary	52.33 Bn	11.23	0.98	25.19 Bn
7	RVMD	Revolution Medicines, Inc.	primary	43.79 Bn	-24.76	-	-
8	INCY	Incyte Corp	primary	25.23 Bn	15.65	4.34	0.04 Bn

Pulmatrix PULM

About

Investment Thesis

Product and Service Breakdown of Revenue (2023)

Product Or Service Breakdown of Revenue (2023)

Peer Comparison

Create an account

Sign In

Reset Password